Engineering Strategies for Allogeneic T Cell-Based Platforms in Cancer Immunotherapy

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Allogeneic T cell therapies present a scalable alternative to autologous treatments for cancer immunotherapy.
• Current platforms primarily utilize alpha-beta (αβ) T cells, but gamma-delta (γδ) T cells, invariant natural killer T cells, and induced pluripotent stem cells are expanding options.

Purpose of the Study:

• To provide a framework for evaluating diverse allogeneic T cell platforms in oncology.
• To discuss engineering strategies for overcoming clinical translation barriers.

Main Methods:

• Review of current allogeneic T cell and T cell-like platforms.
• Analysis of engineering strategies including T cell receptor disruption, HLA modulation, and synthetic circuit design.
• Evaluation of platforms based on clinical maturity, safety, manufacturability, persistence, and tumor-targeting capacity.

Main Results:

• Allogeneic therapies face challenges including immune rejection, limited persistence, toxicity, manufacturing variability, and poor solid tumor efficacy.
• Engineering strategies are being developed to address these limitations.
• A cross-platform framework can guide the development of optimized allogeneic immunotherapies.

Conclusions:

• A shift towards a design-driven paradigm is needed for next-generation allogeneic cellular immunotherapies.
• Integrating platform-specific properties with modular engineering can enhance efficacy, safety, and scalability.
• Optimized allogeneic T cell therapies hold significant promise for improved cancer treatment.